Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil

References

• Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.
   Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, Winkelman JW, Earley CJ, Högl B, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–84.
   PubMed Web of Science ®Google Scholar
• Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286–92.
   PubMed Web of Science ®Google Scholar
• Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics. Sleep Med. 2010;11: 31–7.
   PubMed Web of Science ®Google Scholar
• Berger K. What is clinically significant RLS and who decides about its treatment? Sleep Med. 2010;11:9–10.
   PubMed Web of Science ®Google Scholar
• Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011;26:114–20.
   PubMed Web of Science ®Google Scholar
• Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 2004;5:237–46.
   PubMed Web of Science ®Google Scholar
• Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164:196–202.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16: 283–95.
   PubMed Web of Science ®Google Scholar
• Innes KE, Selfe TK, Agarwal P. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. Sleep Med. 2011;12:623–34.
   PubMed Web of Science ®Google Scholar
• Nagandla K, De S. Restless legs syndrome: pathophysiology and modern management. Postgrad Med J. 2013;89:402–10.
   PubMed Web of Science ®Google Scholar
• Reese JP, Stiasny-Kolster K, Oertel WH, Dodel RC. Health-related quality of life and economic burden in patients with restless legs syndrome. Expert Rev Pharmacoecon Outcomes Res. 2007;7:503–21.
   PubMedGoogle Scholar
• Scholz H, Benes H, Happe S, Bengel J, Kohnen R, Hornyak M. Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study. Health Qual Life Outcomes. 2011;9:73.
   PubMed Web of Science ®Google Scholar
• Sevim S, Dogu O, Kaleagasi H, Aral M, Metin O, Camdeviren H. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry. 2004;75:226–30.
   PubMed Web of Science ®Google Scholar
• Lee HB, Hening WA, Allen RP, Kalaydjian AE, Earley CJ, Eaton WW, et al. Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community. J Neuropsychiatry Clin Neurosci. 2008;20:101–5.
   PubMed Web of Science ®Google Scholar
• Cho SJ, Hong JP, Hahm BJ, Jeon HJ, Chang SM, Cho MJ, et al. Restless legs syndrome in a community sample of Korean adults: prevalence, impact on quality of life, and association with DSM-IV psychiatric disorder. Sleep. 2009;32:1069–76.
   PubMed Web of Science ®Google Scholar
• Hornyak M, Sohr M, Busse M; 604 and 615 Study Groups. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials. Sleep Med. 2011;12:186–9.
   PubMed Web of Science ®Google Scholar
• Ondo W, Romanyshyn J, Vuong KD, Lai D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol. 2004;61:1393–7.
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9–14.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010; 33:81–7.
   PubMed Web of Science ®Google Scholar
• Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174: 1930–3.
   PubMed Web of Science ®Google Scholar
• Allen RP, Ondo WG, Ball E, Calloway MO, Manjunath R, Higbie RL, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12:431–9.
   PubMed Web of Science ®Google Scholar
• Benbir G, Guilleminault C. Pramipexole: new use for an old drug—the potential use of pramipexole in the treatment of restless legs syndrome. Neuropsychiatr Dis Treat. 2006;2:393–405.
   PubMedGoogle Scholar
• Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging. 2013;30:587–92.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Stillman P, Benes H, Buschmann H, Chaudhuri KR, Gonzalez Rodríguez VM, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurol. 2011; 11:28.
   PubMed Web of Science ®Google Scholar
• Silber MH, Becker PM, Earley C, Garcia-Borreguero D, Ondo WG; Medical Advisory Board of the Willis-Ekbom Disease Foundation. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome. Mayo Clin Proc. 2013;88: 977–86.
   PubMed Web of Science ®Google Scholar
• Cundy KC, Annamalai T, Bu L, De Vera J, Estrela J, Luo W, et al. XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004; 311:324–33.
   Google Scholar
• Cundy KC, Sastry S, Luo W, Zou J, Moors TL, Canafax DM. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48:1378–88.
   PubMed Web of Science ®Google Scholar
• HORIZANT US [2013 prescribing information]. Available at: http://www.horizant.com/docs/Horizant_PrescribingInformation.pdf (accessed 23 January 2014).
   Google Scholar
• Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72:439–46.
   PubMed Web of Science ®Google Scholar
• Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW; XP053 Study Group. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282–92.
   PubMed Web of Science ®Google Scholar
• Lal R, Ellenbogen A, Chen D, Zomorodi K, Atluri H, Luo W, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35:165–73.
   PubMed Web of Science ®Google Scholar
• Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, et al.;XP045 Study Group Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32:311–20.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Ellenbogen A, Becker PM, Kushida C, Ball E, Ondo WG, et al. Gabapentin enacarbil in subjects with moderate to severe primary restless legs syndrome with and without severe sleep disturbance: an integrated analysis of subjective and novel sleep endpoints from two studies. J Parkinsonism Restless Legs Syndr. 2013;3:31–40.
   Google Scholar
• Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al.; International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121–32.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4:28–37.
   PubMedGoogle Scholar
• Dancey CP, Reidy J. Statistics without maths for psychology: Using SPSS for Windows, 3rd ed. London: Pearson, Prentice Hall; 2004.
   Google Scholar
• Zhang L, Rainka M, Freeman R, Harden RN, Bell CF, Chen C, et al. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14:590–603.
   PubMed Web of Science ®Google Scholar
• Kohnen R, Allen RP, Benes H, Garcia-Borreguero D, Hening WA, Stiasny-Kolster K, et al. Assessment of restless legs syndrome— methodological approaches for use in practice and clinical trials. Mov Disord. 2007;22(Suppl 18):S485–94.
   PubMedGoogle Scholar
• Inoue Y, Uchimura N, Kuroda K, Hirata K, Hattori N. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry. 2012; 36:251–7.
   PubMed Web of Science ®Google Scholar
• Inoue Y, Shimizu T, Hirata K, Uchimura N, Ishigooka J, Oka Y, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med. 2013;14:1085–91.
   PubMed Web of Science ®Google Scholar
• Kushida CA, Walters AS, Becker P, Thein SG, Perkins AT, Roth T, et al.; XP021 Study Group. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32:159–68.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang Y, Cong SY, Nao JF, Feng J, Bi GR. Efficacy and tolerability of pramipexole for the treatment of primary restless leg syndrome: a meta-analysis of randomized placebo-controlled trials. Neuropsychiatr Dis Treat. 2013;9:1035–43.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Bornemann MA, Kushida CA, Trân PV, Barrett RW; XP060 Study Group. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85:512–21. Erratum in: Mayo Clin Proc. 2010; 85:693–4.
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, DeRossett SE, Hill-Zabala CE. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26:2065–72.
   PubMed Web of Science ®Google Scholar